Published: Fri, April 16, 2021

Third Pfizer COVID-19 vaccine dose ‘likely’ needed within year, CEO says

Third Pfizer COVID-19 vaccine dose ‘likely’ needed within year, CEO says

The Ministry has also said that COVID-19 vaccine can lower the risk among elderly people and the vaccine is safe for pregnant and breast-feeding women.

According to Pfizer, its vaccine is more than 91 percent effective at protecting against COVID-19, and maintains that effectiveness for more than six months, similar to Moderna.

Already receive both doses of the Pfizer or Moderna COVID-19 vaccine?

Pfizer's CEO Albert Bourla on Thursday that COVID-19 vaccine recipients will "likely" need a third dose between six to 12 months after they're fully vaccinated and suggested vaccinations for coronavirus could be needed every year.

During a panel discussion hosted by CNBC in conjunction with CVS Health that aired on Thursday, Albert Bourla said a potential booster shot would be administered six to 12 months of being fully vaccinated.

Based on the data, the CEO said there was a need for re-vaccination between six and 12 months and also an annual re-vaccination.

"There are vaccines that are like polio that one dose is enough. and there are vaccines like flu that you need every year", he continued.

Bulgarian Prime Minister Boyko Borissov explained earlier this week that the Pfizer vaccine's price was rising as sales were being negotiated, costing as much as 19.50 euros, up from 12 euros.

On Thursday, a White House official also said that the U.S. is preparing for the possibility of a booster shot that would be needed between nine and 12 months.

However, more data is needed to determine if protection lasts beyond six months.

A Northewell Health nurse inoculates a sheet metal worker with the first dose of the Pfizer vaccine.

Chief science officer for US President Joe Biden's Covid-19 task force David Kessler said, "We are studying the durability of the antibody response", further adding, "I think for planning purposes, planning purposes only, I think we should expect that we may have to boost".

Ms Walensky said some of these infections have occurred because the vaccinated person did not mount a strong immune response.

In February, the company began testing whether a third shot could offer greater protection against emerging strains of the virus, like the concerning strain first detected in South Africa.

About 144 volunteers will be given the third dose, mostly those who participated in the vaccine's early-stage US testing past year.

Like this: